X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Cancers

期刊標題檢索 CANCERS 最新評論: Do you need three repetitions? (2024-07-01)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Cancers]您好,您是該頁面的第 209512 位訪客。

期刊簡介
期刊名稱Cancers Cancers
LetPub Score
7.6
50 ratings
Rate

Reputation
8.3

Influence
6.8

Speed
9.4

期刊簡稱CANCERS
ISSN2072-6694
h-index53
CiteScore
CiteScoreSJRSNIPCiteScore Rank
8.001.3911.030
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q181 / 404
Category: Medicine
Subcategory: Cancer Research
Q272 / 230

自引率 (2023-2024)11.10%自引率趨勢
掲載範囲
Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
官方網站https://www.mdpi.com/journal/cancers
在線稿件提交https://login.mdpi.com/login?_target_path=https%3A%2F%2Fsusy.mdpi.com%2Fuser%2Flogin%3FauthAll%3Dtrue
開放訪問Yes
出版商MDPI (Basel, Switzerland)
主題領域Medicine
出版國/地區Switzerland
發行頻率
創刊年2009
每年文章數5643每年文章數趨勢
黃金OA百分比99.52%
OA Related Info
APC: Yes( CHF2900; )
APC waiver:No
Other charges: No
Keywords: oncology、tumours、cancer
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ178/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2072-6694%5BISSN%5D
平均審稿時間 *來自出版商的數據: 18.07 Day(s)
來自作者的數據: 11 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Cancers】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Nature CancerH-index: 0

    CiteScore: 31.10
    JAMA OncologyH-index: 41

    CiteScore: 37.50
    JAMA OncologyH-index: 61

    CiteScore: 37.50
    Trends in CancerH-index: 0

    CiteScore: 28.50
    Liver CancerH-index: 25

    CiteScore: 20.80
    Experimental Hematology & OncologyH-index: 0

    CiteScore: 12.60
    ESMO OpenH-index: 0

    CiteScore: 11.70
    Cancer Biology & MedicineH-index: 29

    CiteScore: 9.80
    Annual Review of Cancer BiologyH-index: 0

    CiteScore: 14.50
    Translational Lung Cancer ResearchH-index: 0

    CiteScore: 7.20
    學科內最受檢索的期刊 頁面查看次數
    OncoTargets and Therapy183300
    Cancer Management and Research149110
    Journal of Oncology88245
    Cancer Biology & Medicine58478
    Molecular Therapy-Oncolytics43576
    JAMA Oncology36961
    Liver Cancer34135
    Nature Cancer33325
    Translational Lung Cancer Research29416
    JAMA Oncology28794
  •  

    Cancers Cancers
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/13)
  [Cancers] 的評論撰寫評論
作者: 咏春兴涛


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-07-01 11:31:10 評論於
Do you need three repetitions?
(0) 讚! | 咏春兴涛

作者: 深渊绮晴


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-18 19:19:35 評論於
Early Warning Journal
(0) 讚! | 深渊绮晴

作者: 深渊绮晴


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-18 17:47:13 評論於
2024 Annual Warning Magazine of the Chinese Academy of Sciences
(0) 讚! | 深渊绮晴

作者: 犬走小真


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-28 23:36:09 評論於
I also want to ask
(0) 讚! | 犬走小真

作者: 是你的笑丝呀


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-20 12:25:48 評論於
Could I ask everyone, does every author of this magazine need to click on the "Agree to Publish" in the email?
(0) 讚! | 是你的笑丝呀

作者: 极乐湛恩


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-03 20:58:15 評論於
In the 2023 version, the Chinese Academy of Sciences is divided into sub-districts, with sub-district 3 as a small category
(0) 讚! | 极乐湛恩

作者: 极乐湛恩


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-03 19:09:49 評論於
Now all cancers will be classified as Stage 3
(0) 讚! | 极乐湛恩

作者: 北海白易


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-31 19:33:02 評論於
Research Focus: Tumor Experience Sharing: Will only one cell line be rejected? What else can there be in the mouse metastatic lung cancer model besides llc cells?
(0) 讚! | 北海白易

作者: 极乐园园


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-25 22:35:38 評論於
About 2 days
(0) 讚! | 极乐园园

作者: Kim Micah


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-21 15:07:34 評論於
Review speed: 1.0 | Submission acceptance rate: 95.0 
Emphasized research direction: tumor 
Experience sharing: From submission, review, revision, to acceptance, the whole process is very fast, less than a month. The efficiency of editors and journal staff is very high, and they are also very nice. Currently, it is the recommended journal for submission at our hospital
(0) 讚! | Kim Micah

作者: Kim Micah


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-21 11:37:19 評論於
Accessing meta-analysis, the access speed is also fast
(0) 讚! | Kim Micah

作者: 王源


領域: 医学
審稿時間: 1.0 month(s)
結果: 拒稿


撰寫評論

2023-11-24 18:17:29 評論於
After accepting the offer, the authors all rejected it the next day
(0) 讚! | 王源

作者: 仲夏和平


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-15 08:03:16 評論於
Will it make a difference if the unit is a hospital?
(0) 讚! | 仲夏和平

作者: 不灭问夏


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-13 20:07:42 評論於
How much is the layout fee?
(0) 讚! | 不灭问夏

作者: Kim Micah


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-07 16:45:07 評論於
I received an email from APC on the 10th day of submission, and it is still under external review
(0) 讚! | Kim Micah

作者: 如曼小郎君


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-27 23:20:01 評論於
How many days will the Pending review status last?
(0) 讚! | 如曼小郎君

作者: 上清明喆


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-12 20:33:35 評論於
Be cautious when dealing with domestic hospitals, as they may easily reject you
(0) 讚! | 上清明喆

作者: 士鹏姑娘


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-11 19:35:32 評論於
Magazines do not accept clinical articles
(0) 讚! | 士鹏姑娘

作者: 上清明喆


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-28 09:53:30 評論於
Yes
(0) 讚! | 上清明喆

作者: 上清明喆


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-23 17:45:09 評論於
Research focus on: Cancer; Sharing of experience in immunotherapy: Is it true that hospital-based treatments are more effective?
(0) 讚! | 上清明喆

作者: 卧龙巧荷


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-26 18:06:09 評論於
Hello, is this a hospital in China?
(0) 讚! | 卧龙巧荷

作者: 小野寺硕阳


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-13 12:39:52 評論於
May I ask if you accept meta? Do you accept meta regarding cancer care?
(0) 讚! | 小野寺硕阳

作者: 七星阳州


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-09 17:12:16 評論於
Review speed: 1.0 | Submission hit rate: 50.0
Emphasized research areas: Bioinformatics; Tumors; Experience sharing in bioinformatics: Submission to acceptance in less than a month, around 2 days for review, 5 days for minor revisions, WB requires whole membrane; overall, it's fast, with relatively high innovation requirements
(0) 讚! | 七星阳州

作者: 北国天硕


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-04 13:49:38 評論於
Please translate the following passage into English and Japanese, and use ":" and ":" as headings: 5.2
(0) 讚! | 北国天硕

作者: Rae Leonard


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-06-25 15:42:54 評論於
I am also from a foreign company. How do we handle the matter of sealing?
(0) 讚! | Rae Leonard

首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/13)

開始撰寫 [Cancers] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*